Francis Willard Sarena's Net Worth
$13.4 Million
Who is Francis Willard Sarena?
Francis Willard Sarena has an estimated net worth of $13.4 Million. This is based on reported shares across multiple companies, which include FACET BIOTECH CORP, Apexigen, Inc., PDL BIOPHARMA, INC., FIVE PRIME THERAPEUTICS, INC., and 89bio, Inc..
SEC CIK
Francis Willard Sarena's CIK is 0001423786
Past Insider Trading and Trends
2016 was Francis Willard Sarena's most active year for acquiring shares with 15 total transactions. Francis Willard Sarena's most active month to acquire stocks was the month of December. 2016 was Francis Willard Sarena's most active year for disposing of shares, totalling 24 transactions. Francis Willard Sarena's most active month to dispose stocks was the month of March. 2016 saw Francis Willard Sarena paying a total of $575,668.02 for 188,364 shares, this is the most they've acquired in one year. In 2021 Francis Willard Sarena cashed out on 610,520 shares for a total of $6,634,798.58, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
FACET BIOTECH CORP No price found
VP Gen Counsel & Secy
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -16.28K |
$27.00 | -$439,479.00 |
0
|
Apr 21
| |||
Form 4
| -37.83% | -9.88K |
$27.00 | -$266,625.00 | 16.23K |
Apr 20
| |||
Form 4
| -4.47% | -1.18K |
$16.34 | -$19,313.88 | 25.28K |
Sep 14
| |||
Form 4
| +37.74% | 6.92K |
—
|
—
| 25.27K |
Aug 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 2
| |||
Form 4
| -2.52% | -474.00 |
$6.08 | -$2,881.92 | 18.34K |
Jan 31
| |||
Form 4
| +4,072.28% | 18.37K |
—
|
—
| 18.82K |
Jan 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Apexigen, Inc. No price found
President and COO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -155.42K |
$0.39 |
—
|
0
|
Aug 23
| |||
Form 4
| -4.26% | -6.92K |
$0.49 | -$3,396.94 | 155.42K |
Jun 15
| |||
Form 4
| +390.68% | 129.25K |
$0.40 | -$8,299.20 | 162.34K |
May 23
| |||
Form 4
| -17.29% | -6.92K |
$1.06 | -$7,330.96 | 33.08K |
Dec 15
| |||
Form 4
|
∞
| 40K |
—
|
—
| 40K |
Oct 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
PDL BIOPHARMA, INC. No price found
VP/Gen Counsel/Secy
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -8.52% | -536.00 |
$10.84 | -$5,810.24 | 5.76K |
Sep 15
| |||
Form 4
| +46.60% | 2K |
—
|
—
| 6.29K |
Jan 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
FIVE PRIME THERAPEUTICS, INC. No price found
Chief Strategy Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -99.36% | -123.93K |
$38.00 | -$6,530,414.00 | 795 |
Apr 1 - Apr 16
| |||
Form 4
| -0.93% | -1.16K |
$22.23 | -$25,742.34 | 123.43K |
Feb 26
| |||
Form 4
| -5.14% | -6.75K |
$25.07 | -$169,272.24 | 124.59K |
Feb 24 - Feb 25
| |||
Form 4
| +8.98% | 10.42K |
$16.14 | -$186,949.62 | 126.43K |
Dec 11
| |||
Form 4
| +10.47% | 11K |
$18.00 | -$198,018.00 | 116.01K |
Nov 11
| |||
Form 4
| +34.32% | 26.83K |
$4.85 | -$15,371.13 | 105.01K |
Feb 24 - Feb 26
| |||
Form 4
| -4.95% | -4.07K |
$5.13 | -$20,879.10 | 78.18K |
Feb 5
| |||
Form 4
| -3.30% | -2.81K |
$5.43 | -$15,263.73 | 82.25K |
Sep 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 24
| |||
Form 4
| +11.88% | 8.81K |
$11.95 | -$14,268.30 | 82.95K |
Feb 25 - Feb 26
| |||
Form 4
| -3.88% | -3.00K |
$11.43 | -$34,244.28 | 74.15K |
Feb 5
| |||
Form 4
| +1.27% | 969 |
$13.92 | -$13,279.68 | 77.14K |
Sep 28
| |||
Form 4
| -3.56% | -2.81K |
$14.00 | -$39,340.00 | 76.18K |
Sep 1
| |||
Form 4
| +9.72% | 7K |
—
|
—
| 78.99K |
Feb 26
| |||
Form 4
| -4.17% | -3.13K |
$34.34 | -$107,518.54 | 71.99K |
Mar 1
| |||
Form 4
| -20.85% | -19.78K |
$44.77 | -$885,729.68 | 75.12K |
Mar 1
| |||
Form 4
| +20.40% | 16.08K |
—
|
—
| 94.9K |
Feb 7
| |||
Form 4
|
—
|
0
|
$26.47 | -$152,166.60 | 78.82K |
Scheduled
|
Jan 18
| ||
Form 4
| -3.00% | -2.44K |
$48.60 | -$118,681.20 | 78.82K |
Jan 3
| |||
Form 4
|
—
|
0
|
$32.84 | -$93,366.00 | 81.27K |
Scheduled
|
Nov 28
| ||
Form 4
|
—
|
0
|
$33.44 | -$1,867,598.01 | 81.27K |
Scheduled
|
Nov 23 - Nov 25
| ||
Form 4
| +9.43% | 7K |
—
|
—
| 81.27K |
Sep 8
| |||
Form 4
| -20.85% | -19.57K |
$44.74 | -$875,472.32 | 74.27K |
Sep 1
| |||
Form 4
| +11.93% | 10K |
—
|
—
| 93.83K |
Aug 25
| |||
Form 4
|
—
|
0
|
$24.25 | -$315,155.50 | 83.83K |
Scheduled
|
Mar 29 - Mar 30
| ||
Form 4
|
—
|
0
|
$21.89 | -$800,224.45 | 83.57K |
Scheduled
|
Jan 27
| ||
Form 4
| +875.15% | 75K |
—
|
—
| 83.57K |
Aug 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 17
| |||
Form 4
| +248.37% | 6.11K |
—
|
—
| 8.57K |
Apr 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
89bio, Inc. (ETNB) Snapshot price: $8.47
Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 25K |
—
|
—
| 25K |
Aug 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||